Bristol Myers Squibb Company $BMY Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al

Key Points

• Virginia Retirement Systems reduced its Bristol Myers Squibb stake by 10.5%, selling 181,500 shares and retaining 1.54 million shares valued at approximately $96.1 million. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb reported third-quarter revenue of $13.07 billion and adjusted EPS of $1.35, both above estimates, while revenue rose 6.9% year over year. The company raised its 2026 revenue outlook to approximately $50 billion, although earnings guidance faces pressure from higher deal-related and research charges.
• The stock traded around $62.46 and carries a quarterly dividend of $0.63 per share, representing a 4.0% annualized yield. Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $65.46 amid concerns over Opdivo sales and upcoming patent expirations.

VIRGINIA RETIREMENT SYSTEMS ET Al cut its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 10.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,540,730 shares of the biopharmaceutical company's stock after selling 181,500 shares during the quarter. Bristol Myers Squibb accounts for about 0.6% of VIRGINIA RETIREMENT SYSTEMS ET Al's investment portfolio, making the stock its 25th largest holding. VIRGINIA RETIREMENT SYSTEMS ET Al owned approximately 0.08% of Bristol Myers Squibb worth $96,142,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. lifted its position in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares during the last quarter. State Street Corp grew its holdings in shares of Bristol Myers Squibb by 7.3% in the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company's stock worth $6,093,755,000 after purchasing an additional 7,192,724 shares during the last quarter. Primecap Management Co. CA bought a new position in shares of Bristol Myers Squibb in the second quarter worth approximately $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Bristol Myers Squibb by 0.5% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company's stock worth $1,315,984,000 after buying an additional 119,690 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of Bristol Myers Squibb by 2.9% in the first quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company's stock worth $1,137,847,000 after buying an additional 520,330 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported third-quarter adjusted EPS of $1.35 and revenue of $13.07 billion, exceeding consensus estimates of $1.10 and $12.72 billion, respectively. Revenue increased 6.9% year over year. Bristol Myers Squibb Q3 revenue report
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs—grew 12% to $7.7 billion, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
• Positive Sentiment: Barclays maintained its Buy rating, while management pointed to pipeline progress, cancer-trial data and increased use of artificial intelligence in drug research as potential longer-term catalysts. Barclays maintains Buy rating
• Neutral Sentiment: The improved sales outlook is largely a revenue story: deal-related and higher in-process research and development charges contributed to a reduction in 2026 EPS guidance, and adjusted earnings fell from $1.63 a year earlier to $1.35. BMY earnings and guidance report
• Negative Sentiment: Opdivo sales came in below expectations, highlighting launch execution risks and the continuing challenge of replacing revenue from aging blockbuster drugs. Bristol Myers Opdivo sales report
• Negative Sentiment: Morgan Stanley cut its price target from $41 to $40 and reiterated an Underweight rating, implying substantial downside from the current trading level. Morgan Stanley BMY rating
• Negative Sentiment: A separate analysis downgraded BMY, arguing that progress from newer medicines may not fully overcome the company’s upcoming patent cliffs. Bristol Myers patent-cliff analysis

Bristol Myers Squibb Trading Up 1.7%

NYSE:BMY opened at $62.46 on Friday. The company has a 50-day moving average price of $62.80 and a 200-day moving average price of $59.94. The stock has a market cap of $127.59 billion, a price-to-earnings ratio of 13.85, a P/E/G ratio of 0.32 and a beta of 0.19. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 12 month low of $45.20 and a 12 month high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 62.78%. The company had revenue of $13.07 billion for the quarter, compared to analysts' expectations of $12.72 billion. During the same quarter in the previous year, the company earned $1.63 earnings per share. Bristol Myers Squibb's quarterly revenue was up 6.9% on a year-over-year basis. Equities analysts predict that Bristol Myers Squibb Company will post 6.37 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.0%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb's payout ratio is presently 55.51%.

Wall Street Analysts Forecast Growth

BMY has been the subject of several analyst reports. Citigroup reissued a "neutral" rating and set a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Rothschild & Co Redburn boosted their price objective on shares of Bristol Myers Squibb from $51.00 to $53.00 and gave the company a "neutral" rating in a research report on Thursday, October 8th. Wells Fargo & Company lowered their price objective on shares of Bristol Myers Squibb from $65.00 to $60.00 and set an "equal weight" rating for the company in a research note on Tuesday, October 13th. Bank of America reiterated a "buy" rating on shares of Bristol Myers Squibb in a report on Friday. Finally, Weiss Ratings raised Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, August 18th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $65.46.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.05% of the company's stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.